CVSA
Covista Inc.
CVSA has the edge over F overall, supported by stronger fundamentals and stronger modeled upside.
F
Ford Motor Company
F's outlook is improving, though it still trails on the overall score.
CVSA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Healthy |
CVSA's revenue, profitability, cash flow and balance sheet are all currently healthy.
F Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
F's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
CVSA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6x | $44.17 | -63% |
| Forward | 13x | $119 | — |
| Current | 16x | $119 | — |
| Fair | 18x | $135 | +14% |
| Expensive | 24x | $173 | +46% |
Historical ranges are pointers, not guarantees.
CVSA's PE is in its fair range at 16x. If earnings grow as analysts expect, today's price would be 13x next year's earnings, in its cheap range.
F PE Valuation
F has no meaningful PE right now: it lost money over the past year.
CVSA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
CVSA has the edge over F on the outlook, with more favorable revenue expectations.
F Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect F's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CVSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.18 | +25% |
| Q3 2026 | $7.32 | +9.7% |
| Q2 2026 | $7.04 | +14% |
| Q1 2026 | $6.41 | +7.2% |
| Q4 2025 | $6.80 | +28% |
| Q3 2025 | $6.67 | +54% |
| Q2 2025 | $6.18 | +82% |
| Q1 2025 | $5.98 | +127% |
| Q4 2024 | $5.32 | +96% |
CVSA has the edge over F on earnings quality, reporting a profit while its opponent remains loss making.
F Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.78 | — |
| Q3 2026 | -$1.97 | -270% |
| Q2 2026 | -$1.87 | -340% |
| Q1 2026 | -$1.55 | -224% |
| Q4 2025 | -$2.06 | -241% |
| Q3 2025 | $1.16 | +32% |
| Q2 2025 | $0.78 | -19% |
| Q1 2025 | $1.25 | +29% |
| Q4 2024 | $1.46 | +35% |
F has swung to a loss: it lost $1.97 per share over the past year, after a profit the year before.
CVSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $511.5M | +11% |
| Q2 2026 | $501.4M | +9.7% |
| Q1 2026 | $487M | +4.5% |
| Q4 2025 | $503.4M | +12% |
| Q3 2025 | $462.3M | +11% |
| Q2 2025 | $457.1M | +12% |
| Q1 2025 | $466.1M | +13% |
| Q4 2024 | $447.7M | +14% |
CVSA has the edge over F on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +0.7 points |
| Q2 2026 | 19% | +2.2 points |
| Q1 2026 | 19% | -0.7 points |
| Q4 2025 | 22% | -1.1 points |
| Q3 2025 | 18% | +1.7 points |
| Q2 2025 | 17% | +0.1 points |
| Q1 2025 | 19% | +4.5 points |
| Q4 2024 | 23% | +8.3 points |
CVSA has the edge over F on profitability, with a higher operating margin.
F Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $49.5B | -2% |
| Q2 2026 | $48.3B | -3.8% |
| Q1 2026 | $43.3B | +6.4% |
| Q4 2025 | $45.9B | -4.8% |
| Q3 2025 | $50.5B | +9.4% |
| Q2 2025 | $50.2B | +5% |
| Q1 2025 | $40.7B | -5% |
| Q4 2024 | $48.2B | +4.9% |
F's revenue grew through 2023 and has held roughly level since: $49.5B last quarter, down 2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.9% | -0.1 points |
| Q2 2026 | 1.3% | +0.3 points |
| Q1 2026 | 5.4% | +4.6 points |
| Q4 2025 | -25% | -28 points |
| Q3 2025 | 3.1% | +1.2 points |
| Q2 2025 | 1% | -2.9 points |
| Q1 2025 | 0.8% | -2.1 points |
| Q4 2024 | 2.5% | +3.1 points |
F's operating margin was 2.9% last quarter, about level with the same quarter a year ago.
CVSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $76.4M | -33% |
| Q2 2026 | $97.1M | +139% |
| Q1 2026 | $165.9M | -16% |
| Q4 2025 | $15.1M | +$44.8M |
| Q3 2025 | $114.5M | +45% |
| Q2 2025 | $40.7M | -6.8% |
| Q1 2025 | $197.7M | +40% |
| Q4 2024 | -$29.7M | -$7.3M |
CVSA generated $355M in free cash flow over the past year, up 9.7% from the year before.
F Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.1B | -40% |
| Q2 2026 | $2B | -54% |
| Q1 2026 | -$1.1B | -157% |
| Q4 2025 | $1.1B | +108% |
| Q3 2025 | $5.3B | +50% |
| Q2 2025 | $4.2B | +24% |
| Q1 2025 | $1.9B | +$2.6B |
| Q4 2024 | $530M | +169% |
F has the edge over CVSA on cash flow, with more consistent year-over-year improvement.
CVSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.2% | -1.1M shares |
| 1 year | -6.7% | -2.5M shares |
| 3 years | -18% | -7.6M shares |
| 5 years | -30% | -15.1M shares |
| Available history | -36% | -19.5M shares |
CVSA has the edge over F on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $81M |
| Q2 2026 | — |
| Q1 2026 | $67.5M |
| Q4 2025 | $164.8M |
| Q3 2025 | $7.6M |
| Q2 2025 | $66.7M |
| Q1 2025 | $72.4M |
| Q4 2024 | $40.9M |
CVSA spent $313M buying back its own shares over the past year, up 67% from the year before.
F Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.2% | +89M shares |
| 1 year | +0.7% | +28M shares |
| 3 years | +0.6% | +26M shares |
| 5 years | +1% | +40M shares |
| Available history | +1.8% | +72M shares |
F has 4.1B diluted shares, up 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $311M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $150M |
F spent $311M buying back its own shares over the past year, up 107% from the year before.
CVSA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.9x | Very low |
| Q4 2024 | 1.2x | Healthy |
CVSA's net debt is less than a year of its operating earnings (EBITDA).
F Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.5x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -3.4x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -1.8x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
F has the edge over CVSA on leverage, with a lower net debt burden relative to earnings.
CVSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.3 | Neutral |
| Stochastic | 24.4 | Neutral |
CVSA's weekly RSI is 47 (neutral) and its Stochastic is 24 (neutral).
F Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.5 | Neutral |
| Stochastic | 19.6 | Oversold |
F's weekly RSI is 41 (neutral) and its Stochastic is 20 (oversold).
CVSA PE vs Consumer Cyclical Sector
| Metric | CVSA | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 18x | 9.8% below |
| PE % | 33 | 47 | 14 pts below |
CVSA is trading at 16x earnings, in line with the Consumer Cyclical sector's median of 18x.
F PE vs Consumer Cyclical Sector
| Metric | F | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
F has no meaningful PE right now: it lost money over the past year.
CVSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $123.5 | 3.6% below |
| 20 week MA | $126.4 | 5.8% below |
| 50 week MA | $117.5 | 1.3% above |
| 100 week MA | $116.5 | 2.2% above |
| 200 week MA | $85.9 | 39% above |
CVSA has the edge over F on trend strength, trading above more of its moving averages.
F Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.2 | 2.5% below |
| 20 week MA | $13.3 | 11% below |
| 50 week MA | $13.4 | 11% below |
| 100 week MA | $12.1 | 2% below |
| 200 week MA | $12.1 | 1.4% below |
F is in a downtrend: it's below all five of its weekly moving averages, and 1.4% below its 200-week average.
CVSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.0 | $34.4 | -1.8% |
| 2021 | $34.4 | $30.0 | -13% |
| 2022 | $30.0 | $36.2 | +20% |
| 2023 | $36.2 | $59.0 | +63% |
| 2024 | $59.0 | $90.9 | +54% |
| 2025 | $90.9 | $104.7 | +15% |
| 2026 YTD | $104.7 | $119.0 | +14% |
CVSA has the edge over F on returns for 2026, with the stronger performance.
F Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.36 | $8.86 | -5.3% |
| 2021 | $8.86 | $20.3 | +129% |
| 2022 | $20.3 | $11.4 | -44% |
| 2023 | $11.4 | $12.2 | +7.3% |
| 2024 | $12.2 | $10.0 | -18% |
| 2025 | $10.0 | $13.3 | +33% |
| 2026 YTD | $13.3 | $11.9 | -11% |
F's yearly returns have swung widely, from +129% in 2021 to −44% in 2022. It's down 11% so far in 2026.